Cover Image

Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hind A. Alkhatabi (Author), Samir F. Zohny (Author), Mohammed Razeeth Shait Mohammed (Author), Hani Choudhry (Author), Mohd Rehan (Author), Aamir Ahmad (Author), Farid Ahmed (Author), Mohammad Imran Khan (Author)
Format:	Book
Published:	MDPI AG, 2022-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
by: Laura Giuseppina Di Pasqua, et al.
Published: (2024)

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure
by: James Griffin, et al.
Published: (2023)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019)

Macrophage Polarization and Reprogramming in Acute Inflammation: A Redox Perspective
by: Salvador Pérez, et al.
Published: (2022)

THE GREAT RUSSIAN SCIENTIST M.V. LOMONOSOV
by: G.L. Mikirtichan
Published: (2011)

THE GREAT RUSSIAN SCIENTIST M.V. LOMONOSOV
by: G.L. Mikirtichan
Published: (2011)

Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells
by: Futoon Abedrabbu Al-Rawashde, et al.
Published: (2022)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017)

Estimation of surface dose from therapeutic 6 MV photon beams
by: Lukkana Apipunyasopon
Published: (2013)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020)

On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
by: Nina Žigart, et al.
Published: (2020)

Multi-Omics Approach Reveals Redox Homeostasis Reprogramming in Early-Stage Clear Cell Renal Cell Carcinoma
by: Wei Zhang, et al.
Published: (2022)

Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024)

Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax
by: Niklas J. Koehl, et al.
Published: (2020)

Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis
by: Luis-Amando García González, et al.
Published: (2019)

Nonlinearity in MCF7 Cell Survival Following Exposure to Modulated 6 MV Radiation Fields
by: Laetitia Lacoste-Collin MD, PhD, et al.
Published: (2015)

Leukemic Gingival Enlargement - A Case Report
by: M Anupama, et al.
Published: (2003)

Burkitt's lymphoma in leukemic phase in an Indian boy
by: Vijeev Vasudevan, et al.
Published: (2011)

Morphological spectrum of leukemic mantle cell lymphoma
by: Khaliqur Rahman, et al.
Published: (2012)

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
by: Zhao Y, et al.
Published: (2024)

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
by: Nimita Dave, et al.
Published: (2019)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023)

ANALISIS PEMILIHAN BALLAST WATER TREATMENT SYSTEM (BWTS) PADA KAPAL BULK CARRIER MV.XX
by: Satriyo Yudho Paripurno,
Published: (2023)

Review: Kutsaeva M.V. (2020). Functioning of the Ethnic Language in the Chuvash Diaspora of the Moscow Region, 312
by: Eduard V. Fomin
Published: (2021)

MCNPX Estimation of Photoneutron Dose to Eye Voxel Anthropomorphic Phantom From 18 MV Linear Accelerator
by: Ali AA Alghamdi
Published: (2023)

Microgramma vacciniifolia frond lectin (MvFL) exhibits antitumor activity against sarcoma 180 in mice
by: Leydianne Leite de Siqueira Patriota, et al.
Published: (2021)

Differences between leukemic arthritis and juvenile idiopathic arthritis
by: Alfonso Ragnar Torres Jimenez, et al.
Published: (2023)

Grandisin induces apoptosis in leukemic K562 cells
by: Alane Pereira Cortez, et al.
Published: (2017)

ANALISIS EFEK LIKUEFAKSI BIJI NIKEL PADA STABILITAS DAN OLAH GERAK KAPAL MV. NUR ALLYA
by: Fanny Darwani Putri,
Published: (2024)

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey
by: Katarzyna Bobeff, et al.
Published: (2023)

Macrophages sensing oxidized DAMPs reprogram their metabolism to support redox homeostasis and inflammation through a TLR2-Syk-ceramide dependent mechanism
by: Vlad Serbulea, et al.
Published: (2018)

DENTAL MANAGEMENT NEEDS OF HOSPITALIZED LEUKEMIC PATIENTS (CASE REPORT)
by: Indriasti Indah Wardhany, et al.
Published: (2015)

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
by: Hasina Maredia, MD, et al.
Published: (2021)

Diffuse large B-cell lymphoma presenting in the leukemic phase
by: Patricia Puccetti Pires, et al.
Published: (2016)

A young leukemic patient with unusual catastrophic intestinal complication
by: Kim Vaiphei, et al.
Published: (2015)

Efektivitas Aplikasi Mobile Learning Role Play Games (RPG) Maker MV untuk Meningkatkan Kemampuan Berpikir Kritis
by: Abdur Rasyid, et al.
Published: (2020)

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor
by: Ahmed Hamed Salem, et al.
Published: (2024)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
by: Qiang Cao, et al.
Published: (2023)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions
by: Johanna Weiss, et al.
Published: (2016)